Exploratory analyses of OS in clinical and molecular subgroups. (A) According to age (>60 years or <60 years). (B) According to FLT3 mutation type. (C) According to AR for patients with FLT3-ITD mutation. (D) According to genomic subgroup (CBF AML, NPM1^mut AML, and others). TKD, tyrosine kinase domain.